Brief: Larimar Therapeutics Q4 Net Income USD -12.993 Million
Mar 14 (Reuters) - Larimar Therapeutics Q4 operating expenses USD 14.162 million. * Q4 basic EPS USD -0.3 * Q4 income from operations USD -14.162 million
Recent news on Larimar Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Regenxbio, Repay, Natera, Fortune Brands
Larimar tumbles as safety concerns resurface in rare disease drug study update
U.S. STOCKS ON THE MOVE-Regenxbio, Repay, Natera, Fortune Brands
U.S. STOCKS ON THE MOVE-SpaceX, Charter, Gulfport Energy
Larimar tumbles as safety concerns resurface in rare disease drug study update